Description
Product details
Morenam Injection is an injectable antibacterial medicine containing Meropenem, a broad-spectrum carbapenem antibiotic used for the treatment of serious bacterial infections caused by susceptible organisms. Meropenem works by interfering with bacterial cell-wall synthesis, resulting in bacterial cell death. It has activity against a broad range of Gram-positive and Gram-negative bacteria, including many organisms responsible for complicated or severe infections. Morenam SB 1.5 g Injection combines a carbapenem antibiotic with Sulbactam, a beta-lactamase inhibitor. Sulbactam can inhibit certain bacterial beta-lactamase enzymes and also has intrinsic activity against some Acinetobacter species. The clinical role of the combination depends on the exact formulation, susceptibility pattern, and locally approved indication. These injectable antibiotics should be used according to culture/susceptibility results and antimicrobial-stewardship principles whenever appropriate. Available Variants Product Composition Strength Morenam 500 mg Injection Meropenem 500 mg Morenam 1 g Injection Meropenem 1 g Morenam SB Injection Meropenem + Sulbactam* 1.5 g total Dosage The dose, frequency, and duration should be determined by a qualified healthcare professional based on: Type and severity of infection Susceptibility of the causative organism Patient's age and body weight Kidney function Clinical response Exact product formulation Meropenem is administered intravenously. Significant renal impairment generally requires dosage adjustment. Precautions Check for previous allergy to carbapenems, penicillins, cephalosporins, or other beta-lactam antibiotics. Kidney function should be assessed, particularly in patients with renal impairment. Inform the physician about a history of seizures or other CNS disorders. Prolonged antibiotic use may result in overgrowth of non-susceptible organisms. Severe or persistent diarrhea should be evaluated for Clostridioides difficile-associated diarrhea. Meropenem can significantly reduce blood concentrations of valproic acid/valproate, potentially increasing seizure risk. Pregnancy and breastfeeding require appropriate medical assessment. Side Effects Possible adverse effects include: Nausea Vomiting Diarrhea Headache Rash Injection-site reactions Changes in liver enzymes Less common but serious adverse reactions can include: Severe hypersensitivity/anaphylaxis Seizures Severe skin reactions Antibiotic-associated colitis Blood-cell abnormalities Warning Morenam and Morenam SB Injections are prescription antibiotics intended for administration under qualified medical supervision. They should only be used for confirmed or strongly suspected susceptible bacterial infections. Unnecessary or inappropriate antibiotic use contributes to antimicrobial resistance. FAQ 1. What is Morenam Injection used for? Assuming the product contains meropenem, it is used for the treatment of serious bacterial infections caused by susceptible organisms. 2. What strengths of Morenam are available? The listed variants are Morenam 500 mg and Morenam 1 g Injection. 3. What is Morenam SB 1.5 g? Based on the information supplied, Morenam SB is a formulation involving Sulbactam. Please verify the complete composition and individual ingredient strengths from the product pack. 4. What is Sulbactam? Sulbactam is a beta-lactamase inhibitor that can inhibit certain bacterial enzymes responsible for resistance to beta-lactam antibiotics. 5. Is Morenam used for viral infections? No. Antibiotics such as meropenem do not treat viral infections such as the common cold or influenza. 6. Does kidney disease affect the dosage? Yes. Meropenem is substantially eliminated through the kidneys, so dose adjustment may be necessary in renal impairment. 7. Can Meropenem interact with Valproate? Yes. Meropenem can substantially decrease valproic acid/valproate concentrations, which may reduce seizure control. 8. Is Morenam Injection prescription-only? Yes. Injectable carbapenem antibiotics should be used under qualified medical supervision and appropriate antimicrobial stewardship.
